Chester County News and Community Website
WILMINGTON, DE — AOP Health US has begun commercial use of Rapiblyk, an intravenous heart rhythm treatment approved by the U.S. Food and Drug Administration last year, as hospitals seek …
AOP Health Begins U.S. Rollout of Heart Rhythm Drug Read More
WILMINGTON, DE — The U.S. Food and Drug Administration recently approved RAPIBLYK® (landiolol) for pediatric patients from birth to under 18 years old with supraventricular tachycardia, expanding its use beyond …
FDA Approves Rapiblyk for Pediatric SVT Patients in U.S. Read More
WILMINGTON, DE — AOP Health US, LLC has been awarded a national group purchasing agreement with Premier, Inc., allowing Premier members to access pre-negotiated pricing and terms for Rapiblyk (landiolol), …
AOP Health US Secures Premier Purchasing Agreement for Rapiblyk Read More
WILMINGTON, DE — AOP Health US, LLC announced that Rapiblyk® (landiolol), a recently introduced critical care therapy, is now more widely available nationwide through a contract with Vizient®, the country’s …
Critical Heart Drug Expands Access Through National Contract Read More